LifeArc Ventures 2025: New geographies and investments, a growing team and continued portfolio progress

Core Insights - LifeArc Ventures had its most active year in 2025, announcing investments in four new life sciences companies and supporting a portfolio of 20 companies by year-end [1][2] - The portfolio has expanded through Seed and Series A investments, with a shift to Series B investments in 2025, indicating a growth trajectory [2] - LifeArc Ventures aims for substantial progress in 2026, with multiple clinical starts and new investments anticipated [2] Investment Strategy - LifeArc Ventures has diversified its portfolio geographically, making its first investments in German, Swiss, and Scandinavian companies while maintaining a focus on the UK [3] - The investment strategy encompasses a broad range of therapeutics and tech-enabled biotechnology across various modalities and therapeutic areas [3] - The organization also runs a fund of funds strategy, having invested in ten leading global life sciences venture funds to support long-term financial sustainability [3] Team Expansion - The appointments of Olivia Cavlan as Partner and Diana Röttger as Investment Principal in 2025 enhanced LifeArc Ventures' commercial, operational, and scientific expertise [4] - This expansion aims to improve the sourcing and management of promising investments and support the growth of existing portfolio companies [4] Portfolio Highlights - LifeArc Ventures invested in several high-impact companies, including: - GlycoEra AG's $130 million Series B to advance its clinical stage targeting autoimmune conditions [6] - Hillstar Bio's $67 million Series A focused on precision immunotherapies [6] - Exciva's €51 million Series B for Alzheimer's treatment [6] - Tribune Therapeutics' €23 million Series A for idiopathic pulmonary fibrosis [6] - Additional investments included Maxion Therapeutics' $72 million Series A and Affect Therapeutics' $26 million Series B, showcasing a focus on innovative therapies and technologies [8] Achievements and Progress - LifeArc Ventures' portfolio companies made significant strides in 2025, including expanding intellectual property, strengthening leadership, and forming strategic alliances [7] - Notable advancements included positive FDA feedback for Ikarovec's dual pathway gene therapy and RQ Bio's development of long-acting antibodies for seasonal influenza [8]